Kestra Medical Technologies, Ltd. (KMTS) Q1 2026 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported a strong start to fiscal Q1 2026, with revenue increasing 52% year-over-year to $19.4 million and prescriptions for its ASSURE system rising 51%, reflecting significant market share gains. Gross margin expanded for the seventh consecutive quarter to 45.7%, driven by a higher in-network payer mix, now approaching 80%, and improved unit economics, with management confident in achieving 70%+ long-term margins. The company raised its full-year FY26 revenue guidance to $88 million, a 47% increase, underscoring confidence in continued commercial expansion and operating leverage despite ongoing net and adjusted EBITDA losses. A key clinical milestone was also announced: the conclusion of enrollment for its 24,000-25,000 patient FDA post-approval study, with results slated for a late-breaker presentation at the American Heart Association Scientific Sessions, which is expected to provide substantial clinical evidence supporting the ASSURE system in the underutilized WCD market.

Analysis

Kestra Medical Technologies (KMTS) reported a robust start to fiscal 2026, with Q1 revenue growing 52% year-over-year to $19.4 million, directly driven by a 51% increase in prescriptions for its ASSURE system. This performance reflects accelerating market share capture, which management estimates now stands at approximately 12% of the underpenetrated WCD market. Profitability metrics showed significant improvement, with gross margin expanding for the seventh consecutive quarter to 45.7% from 32.9% in the prior-year period. This expansion is attributed to improved unit economics, including a 20% reduction in cost-per-fit and, critically, a higher mix of in-network patients, which has climbed from 70% at the time of the IPO to nearly 80%. The higher payer coverage is boosting the cash conversion rate, which reached 47%. Despite a GAAP net loss of $25.8 million driven by investments in commercial expansion, the company raised its full-year revenue guidance to $88 million, signaling strong confidence in its growth trajectory. A key forward-looking catalyst is the conclusion of its 24,000-25,000 patient FDA post-approval study, with results slated for a late-breaker presentation at the American Heart Association Scientific Sessions in November. Management expects this data to be the largest study in the WCD category, positioning it to definitively address competitive claims about a lack of clinical evidence.

Key Decisions for Investors

• The sustained 50%+ prescription growth and upwardly revised guidance validate the commercial expansion strategy; investors should monitor the pace of sales territory additions and rep productivity as leading indicators of continued market share gains from the incumbent.
• The direct correlation between the rising in-network payer mix, now approaching 80%, and the 1,280 basis point year-over-year gross margin expansion is the core of the profitability thesis, making the cash conversion rate a critical metric to track for progress toward the 70%+ long-term margin target.
• The upcoming late-breaker presentation of the 25,000-patient post-approval study at the AHA conference is a significant near-term catalyst that could neutralize a key competitive disadvantage and accelerate adoption, warranting close attention.
• While the top-line narrative is strong, investors should balance this against the ongoing cash burn, evidenced by a $19.4 million adjusted EBITDA loss, and assess whether the pace of operating leverage is sufficient to reach cash flow breakeven with the existing $201.2 million cash balance.